Clinical Efficacy and Safety of Two Cycles of Intra-Articular Injection of Porcine Atelocollagen Versus Hyaluronic Acid in Knee Osteoarthritis
Bioengineering · 29.06.2025 · 12 (7) · 710
DOI: 10.3390/bioengineering12070710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering, online erschienen am 29.06.2025. Verfasst von Yong In und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seo…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Research Fund of Seoul St. Mary's Hospital , The Catholic University of Korea, Research Fund of Seoul St. Mary’s Hospital, the Catholic University of Korea.
Abstract (Originalsprache)
(1)
Background
Knee osteoarthritis (KOA) induces pain, stiffness, and impaired mobility, particularly in aging populations. Despite providing symptom relief, the long-term efficacy of intra-articular hyaluronic acid (HA) injections remains unclear. With its longer intra-articular residence time and potential chondroprotective effects, porcine-derived atelocollagen is an alternative to HA. We aimed to compare the safety and efficacy of collagen versus HA injections in symptomatic KOA. (2)
Methods
This retrospective observational study included 40 patients with KOA who received either two cycles of collagen or HA injections at 6-month intervals. Clinical outcomes were assessed using the visual analog scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and 6 months after the first and second injections (Cycle 1 and Cycle 2, respectively). Patient satisfaction and adverse events were recorded. Non-inferiority analysis was conducted for VAS and WOMAC score changes. (3)
Results
Significant intragroup improvements in VAS and WOMAC scores were noted after each injection cycle (p < 0.05), albeit without significant between-group differences, non-inferiority of collagen to HA based on predefined margins, and comparable patient-reported satisfaction (>85% reported improvement after each cycle), with similar incidence of mild adverse events (collagen: 20%, HA: 25%, p = 0.705). (4)
Conclusions
Intra-articular collagen injections were clinically non-inferior to HA in reducing pain and improving function in patients with KOA across two treatment cycles. Given its favorable safety profile and potential structural benefits, collagen may serve as a viable alternative injectable therapy for the non-surgical management of KOA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
ORCID-Profile: Yong In, Keun Young Choi, Man Soo Kim
Förderung
- National Research Foundation of Korea
- Research Fund of Seoul St. Mary's Hospital , The Catholic University of Korea
- Research Fund of Seoul St. Mary’s Hospital, the Catholic University of Korea
Zitieren
APA
In, Y., Choi, K. Y., & Kim, M. S. (2025). Clinical Efficacy and Safety of Two Cycles of Intra-Articular Injection of Porcine Atelocollagen Versus Hyaluronic Acid in Knee Osteoarthritis. Bioengineering, 12(7), 710. https://doi.org/10.3390/bioengineering12070710
Vancouver
In Y, Choi KY, Kim MS. Clinical Efficacy and Safety of Two Cycles of Intra-Articular Injection of Porcine Atelocollagen Versus Hyaluronic Acid in Knee Osteoarthritis. Bioengineering. 2025;12(7):710. doi:10.3390/bioengineering12070710
BibTeX
@article{In2025,
author = {In, Yong and Choi, Keun Young and Kim, Man Soo},
title = {Clinical Efficacy and Safety of Two Cycles of Intra-Articular Injection of Porcine Atelocollagen Versus Hyaluronic Acid in Knee Osteoarthritis},
journal = {Bioengineering},
year = {2025},
volume = {12},
number = {7},
pages = {710},
doi = {10.3390/bioengineering12070710}
}
EUVIMED